$CEMI News
Last published 3y ago
- 3y agoCEMIAPTVLife Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial OfficerPR NewswireLife Science Outsourcing, Inc. ("LSO"), a premier contract manufacturer and value-added service provider for the medical device and life science...
- 3y agoCEMIChembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023GlobeNewswireMEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders
- 3y agoCEMIBiosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.GlobeNewswireSTRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger
- 3y agoCEMIChembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023GlobeNewswireMEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders
- 3y agoCEMIChembio's CEO Letter to StockholdersGlobeNewswireMEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders
- 3y agoCEMIBiosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.GlobeNewswireSTRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger
- 3y agoCEMIChembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023GlobeNewswireMEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders
- 3y agoCEMIBiosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.GlobeNewswireSTRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger
- 3y agoCEMIChembio Announces Letter to Stockholders Regarding Tender OfferGlobeNewswireMEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to
- 3y agoCEMIChembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis SystemGlobeNewswireMEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory
- 3y agoALBOALRCEMILPTXMoore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoALRATCXCEMILPTXMoore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law FirmPR NewswireNEW YORK, Feb. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoCEMIBiosynex and Chembio Diagnostics Announce Definitive Acquisition AgreementGlobeNewswireComplementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings
- 3y agoCEMIChembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis SystemGlobeNewswireHAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U.S. Food
- 4y agoCEMIChembio Diagnostics Reports Third Quarter 2022 Financial ResultsGlobeNewswireHAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported
- 4y agoCEMIChembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022GlobeNewswireHAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial
- 4y agoCEMIChembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm AssayGlobeNewswireHAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers
- 4y agoCEMIChembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test DevelopmentGlobeNewswireHAUPPAUGE, N.Y., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is evaluating the potential to develop a monkeypox ra
- 4y agoCEMIChembio Diagnostics Reports Second Quarter 2022 Financial ResultsGlobeNewswireHAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended
- 4y agoCEMIChembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022GlobeNewswireHAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 202
- 4y agoCEMIChembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial ChannelGlobeNewswireHAUPPAUGE, N.Y., June 15, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel
- 4y agoCEMIChembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of DirectorsGlobeNewswireHAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Dire
- 4y agoCEMIChembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio's HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia FacilityGlobeNewswireHAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into a manufacturing agreement with Reszon
- 4y agoCEMIChembio Diagnostics Reports First Quarter 2022 Financial ResultsGlobeNewswireHAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended M
- 4y agoCEMIChembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022GlobeNewswireHAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 202
- 4y agoCEMIChembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireHAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and y
- 4y agoCEMIChembio Diagnostics to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022GlobeNewswireHAUPPAUGE, N.Y., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and fu
- 4y agoCEMIChembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHAUPPAUGE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has gra
- 4y agoCEMIChembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial OfficerGlobeNewswireHAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer e
- 4y agoCEMIChembio Diagnostics Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test SystemGlobeNewswireHAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has submitted a De Novo/510(k) Request to the U.S. Food an
- 4y agoAPDNCEMICODXPRPO+1Thinking about buying stock in Applied DNA Sciences, Co-Diagnostics, Precipio, Beyond Air, or Chembio Diagnostics?PR NewswireNEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, CODX, PRPO, XAIR, and CEMI.
- 4y agoCEMIChembio Diagnostics Receives SAHPRA Approval for DPP SARS-CoV-2 Antigen TestGlobeNewswireHAUPPAUGE, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt on November 26, 2021, of South Africa Health Products Regu
- 4y agoCEMIChembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) LtdGlobeNewswireHAUPPAUGE, N.Y., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostic Systems Inc. ("Chembio"), a subsidiary of Chembio Diagnostics, Inc. (NASDAQ:CEMI), received an international arbitration award Thursday, November 18, 2021 against BioSure (UK) Ltd, C
- 4y agoCEMIChembio Diagnostics Submits EUA Application for New DPP SARS-CoV-2 Antigen TestGlobeNewswireHAUPPAUGE, N.Y., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application
- 4y agoCEMIChembio Diagnostics Announces Extension of Delivery Schedule for Bio Manguinhos Purchase Order of DPP SARS-COV-2 Antigen TestsGlobeNewswireHAUPPAUGE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the delivery schedule for shipments of DPP SARS-COV
- 5y agoCEMIChembio Diagnostics Reports Third Quarter 2021 Financial ResultsGlobeNewswireHAUPPAUGE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended
- 5y agoCEMIChembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021GlobeNewswireHAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021
- 5y agoCEMIChembio Announces EUA Submission for DPP Respiratory Antigen PanelGlobeNewswireHAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) applicatio
- 5y agoCEMINNVCOPTISENSDemand for Disinfectant Products Continues to Grow Despite the Containment of the PandemicPR NewswireNEW YORK, Sept. 21, 2021 /PRNewswire/ -- The economy has shown signs of recovery, but fears related to the pandemic and its new variants remain. Last year, the World Health Organization (WHO) published a list of medical devices required, broken down into
- 5y agoAHPIAPTCEMIOPTI+1An Innovative Approach is Needed to Manage a Growing Demand for Medical SuppliesPR NewswireNEW YORK, Sept. 14, 2021 /PRNewswire/ --A hospital's need for medical equipment and supplies is been influenced by several major factors. These include an aging population, increasing occurrences of infectious diseases, methods such as frequent glove swa
- 5y agoCEMIGNLNQFINREKR+1Thinking about buying stock in Rekor Systems, Greenlane, Sonim Technologies, Chembio Diagnostics, or 360 DigiTech?PR NewswireNEW YORK, Sept. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for REKR, GNLN, SONM, CEMI, and QFIN.
- 5y agoCEMINOVNOGENOPTI+1Powerful Software Plays a key Role in Keeping the Pandemic at BayPR NewswireNEW YORK, Sept. 8, 2021 /PRNewswire/ -- The pandemic has helped to increase awareness of the importance of maintaining hygiene to avoid transmission of pathogens in healthcare facilities and among the general populous. According to data provided by Gran
- 5y agoADILCEMIGSATMOGU+1Thinking about buying stock in Chembio Diagnostics, Mogu, Adial Pharmaceuticals, Globalstar, or RedHill Biopharma?PR NewswireNEW YORK, Aug. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, MOGU, ADIL, GSAT, and RDHL.
- 5y agoCEMIChembio Launches Commercial Distribution of Third-Party COVID-19 Antigen AssayGlobeNewswireHAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Auth
- 5y agoCEMIChembio Diagnostics Reports Second Quarter 2021 Financial ResultsGlobeNewswireHAUPPAUGE, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended
- 5y agoBTBTCEMILYFTTELL+1Thinking about buying stock in Tellurian, Chembio Diagnostics, Wheeler Real Estate, Bit Digital, or Lyft?PR NewswireNEW YORK, Aug. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TELL, CEMI, WHLR, BTBT, and LYFT. To
- 5y agoBEKECEMIEDUITRM+1Thinking about buying stock in New Oriental Education, Iterum Therapeutics, Tencent Music Entertainment, KE Holdings, or Chembio Diagnostics?PR NewswireNEW YORK, July 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDU, ITRM, TME, BEKE, and CEMI. To
- 5y agoAZRXCEMIGETAL+1Thinking about buying stock in TAL Education, Chembio Diagnostics, AzurRx BioPharma, Summit Wireless Technologies, or General Electric?PR NewswireNEW YORK, July 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAL, CEMI, AZRX, WISA, and GE. To s
- 5y agoCEMIChembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021GlobeNewswireHAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 202
- 5y agoCEMIChembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global FundGlobeNewswireHAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $4 million purchase order from the Partnership fo